Biomarkers of Ovarian Cancer Progression
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Biomarkers".
Deadline for manuscript submissions: 30 April 2025 | Viewed by 204
Special Issue Editor
Special Issue Information
Dear Colleagues,
The clinical management of ovarian cancer is highly challenging for several reasons, such as high rates of late diagnosis and tumor recurrence. The five-year survival rate of ovarian cancer patients, which is about 45% in general and 30% for patients diagnosed with late-stage tumors, has changed very little over the past decade. Most patients undergo debulking surgery and platinum–paclitaxel combination chemotherapy. During and after the initial treatment, prognostic biomarkers with sensitivity and specificity are crucial when it comes to monitoring patients’ response to treatment and the progression or recurrence of ovarian cancer. Serum and tissue-based biomarkers have been investigated with the hope of developing clinical tools to assess or predict the development of ovarian cancer. Over the past ten years, many researchers have focused their efforts on researching this field, aiming to transform the treatment of patients with ovarian cancer and improve their survival rate.
In this Special Issue of Cancers, we invite experts in the field to contribute research papers that address our current understanding and challenges in the development of potential biomarkers for detecting the progression of ovarian cancer.
Dr. Yang Yang-Hartwich
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- ovarian cancer
- biomarkers
- prognosis
- blood biomarkers
- tissue biomarkers
- tumor progression
- treatment response
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
